140 related articles for article (PubMed ID: 35974101)
21. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.
Ghobrial IM; Habermann TM; Ristow KM; Ansell SM; Macon W; Geyer SM; McGregor CG
Leuk Lymphoma; 2005 Feb; 46(2):191-6. PubMed ID: 15621801
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
Choquet S; Leblond V; Herbrecht R; Socié G; Stoppa AM; Vandenberghe P; Fischer A; Morschhauser F; Salles G; Feremans W; Vilmer E; Peraldi MN; Lang P; Lebranchu Y; Oksenhendler E; Garnier JL; Lamy T; Jaccard A; Ferrant A; Offner F; Hermine O; Moreau A; Fafi-Kremer S; Morand P; Chatenoud L; Berriot-Varoqueaux N; Bergougnoux L; Milpied N
Blood; 2006 Apr; 107(8):3053-7. PubMed ID: 16254143
[TBL] [Abstract][Full Text] [Related]
24. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
25. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.
Trappe R; Hinrichs C; Appel U; Babel N; Reinke P; Neumayer HH; Budde K; Dreyling M; Dührsen U; Kliem V; Schüttrumpf S; Hauser IA; Mergenthaler HG; Schlattmann P; Anagnostopoulos I; Doerken B; Riess H
Am J Transplant; 2009 Oct; 9(10):2331-7. PubMed ID: 19663889
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
27. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
28. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
29. EBV and posttransplantation lymphoproliferative disease: what to do?
Zimmermann H; Trappe RU
Hematology Am Soc Hematol Educ Program; 2013; 2013():95-102. PubMed ID: 24319169
[TBL] [Abstract][Full Text] [Related]
30. Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
Liu Y; Sun LY; Zhu ZJ; Wei L; Qu W; Wang L; Yuan LL; Zeng ZG
Int J Clin Pract; 2021 Apr; 75(4):e13843. PubMed ID: 33222369
[TBL] [Abstract][Full Text] [Related]
31. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI
Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
[TBL] [Abstract][Full Text] [Related]
32. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).
Oertel SH; Verschuuren E; Reinke P; Zeidler K; Papp-Váry M; Babel N; Trappe RU; Jonas S; Hummel M; Anagnostopoulos I; Dörken B; Riess HB
Am J Transplant; 2005 Dec; 5(12):2901-6. PubMed ID: 16303003
[TBL] [Abstract][Full Text] [Related]
33. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
34. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.
Tai R; Tirumani SH; Tirumani H; Shinagare AB; Hornick JL; Ramaiya NH
Br J Radiol; 2015 Aug; 88(1052):20140861. PubMed ID: 25989696
[TBL] [Abstract][Full Text] [Related]
35. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
[TBL] [Abstract][Full Text] [Related]
36. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
[TBL] [Abstract][Full Text] [Related]
37. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination.
Gupta S; Fricker FJ; González-Peralta RP; Slayton WB; Schuler PM; Dharnidharka VR
Pediatr Transplant; 2010 Nov; 14(7):896-902. PubMed ID: 20642490
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Kuriyama T; Kawano N; Yamashita K; Ueda A
J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
[TBL] [Abstract][Full Text] [Related]
39. Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children.
Giraldi E; Provenzi M; Conter V; Colledan M; Bolognini S; Foglia C; Sebastiani R; Fiocchi R; Gianatti A; DʼAntiga L; Rambaldi A
Transplantation; 2016 Feb; 100(2):437-45. PubMed ID: 26270449
[TBL] [Abstract][Full Text] [Related]
40. Long-term remission in an adult heart transplant recipient with advanced Burkitt's lymphoma post-transplant lymphoproliferative disorder after anthracycline-free chemotherapy: A case report and literature review.
AbdelHameid D; Felice A; Cooper LB; Katugaha SB
Transpl Infect Dis; 2020 Aug; 22(4):e13265. PubMed ID: 32077552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
